Septerna, Inc.
Advancing novel small molecule GPCR medicines for endocrine, immune, and metabolic diseases.
SEPN | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 250 EAST GRAND AVENUE, SUITE 65, 94080 SOUTH SAN FRANCISCO
- Website:
- https://septerna.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Septerna, Inc. is a biotechnology company focused on discovering and advancing novel small molecule medicines that target G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform™ to enable the development of new drugs. Septerna is advancing a wholly-owned pipeline with an initial focus on treatments for endocrinology, immunology, inflammation, and metabolic diseases. Its lead candidate, SEP-631, is an oral small molecule in Phase 1 clinical trials for mast cell-driven diseases. The company also has a collaboration with Novo Nordisk to develop medicines for obesity and other cardiometabolic diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Septerna, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Septerna, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Septerna, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
